Immunocount Presentation

5/28/2018 Immunocount Presentation

1/22

ImmunoCount (IC)

March 2009

Confidential please do not distribute without prior permission.


2/22

Highlights

Suffering

Gap

Innovation

Leadership

Revenue

Company

33 million People are Living With HIV/AIDS (PLWHA)

Lack of low cost, simplified CD4/CD8 testing solutions

IC is filling the gap and has been approved by the Indian CentralDrugs Control Administration (CDSCO) (FDA equivalent). 4 more products are ready for CDSCO approval and patent process.

Strong management team with relevant healthcare , researchand business experience.

Purchase approved in India and Zambia.

Founded in 1997 with focus on developing simplified tests forunderserved markets


3/22

Background

Estimated 33 million PLWH and 8 million with AIDS

PLWHA should be tested 2 to 3 times = minimum 66 million tests annually

70% of 33 million PLWHA are in developing countries

70% of PLWHA in developing countries are not properly tested, ICs market

Only 31% of people who needed HIV treatment had access to it by end-2007.

Once the CD4 count reaches below 200, Antiretroviral Therapy (ART) forPLWHA is paid by the UN

This is a major motivation for PLWHA to be tested regularly

Source (WHO)


4/22

IC Solution

IC test measure CD4/CD8 cell count for PLWHA to monitor theprogression of the disease

IC is a low cost solution and easy to use product geared towards servingrural areas in the developing world

IC is approved by CDSCO and has a patent

CDSCO approval permits IC to market in Africa and Asia


5/22

Solving the pain

Readily availableLowHighTechnician skill

LowHighMaintenance

CleanSterileEnvironment

Less training requiredLow skilledtechnician toneeded to manage

the process

High skilledtechnician requiredto operate the

machine

Process

Portable and able toreach the masses

Ideal for peri-urban& rural areas withlow testing volume

Suitable forurban area with hightesting volume

Benefit

Price competitive$10$15 to $25Selling price/test

Only a microscope needed$400$50,000+Capital expense

IC advantageImmunoCountFlow Cytometer


6/22

Universal Access 2010

Funding Sources:

World Bank, WHO, Global AIDS Fund, Gates Foundation, ClintonFoundation, and many others

At the end of 2007, the gap between required and available funding was

estimated to be US$ 8.1 billion. To meet universal access targets,funding will have to more than quadruple to US$ 35 billion in 2010 andto US$ 41 billion in 2015. (Source: WHO)

Simplified and low cost solutions, such as ImmunoCount will be neededto serve the masses and reach the rural areas


7/22

Product Testing & Validation

India: Third party has successfully evaluated and approved IC tests for India NACO has authorized purchase of 100,000 tests

Zambia: University of Lusaka Teaching Hospital (UTH) has evaluated and approved the

product to the Ministry of Health Zambia team has introduced the product and received positive response from

Congo, Mozambique, and Angola

Following is the conclusion from UTH report:

The IC is the best new technology for peri-urban and rural areas of Zambia withlow cost.

South Africa: Nelson R. Mandela School of Medicine has approved the field evaluation process


8/22

Management

Dr. Subhash HiraFounder & Chairman

Harish MamtaniPresident & CEO

Rajni Shivani, PhDTechnical Director

Dr. Vishwas Sarangdhar

BiotechnologyConsultant

Dr. Hira has been involved in HIV/AIDS field since 1980with primary focus on Africa and Asia. Dr. Hira is theWorld Bank Program Leader for HIV/AIDS in India.

Investment management background. Actively invests inpublic and private markets.

Responsible for QA and managing the productionprocess.

Has played an active role in new technology and productdevelopment. Previously worked with Reliance LifeSciences .


9/22

Post Funding Next 12 Months

$2 million funding allows IC to achieve the following tasks

3 months: Secure real estate for R&D lab and manufacturing facilities in India Close contract with India or Zambia for 200,000 IC tests

6 months: Begin delivering product to NACO, Zambia, and others in phases over the next 6 months.

Close contract for additional 200,000 tests Apply for WHO pre-qualification so third party evaluation is not required at each country level Complete development of rapid CD4 test kit (new technology) Submit 4 products for CDSCO approval (6 month process)

9 months: Complete product development for 4 more R&D products for a total of 9 products

12 months: Have infrastructure in place to penetrate top 10 markets Complete facilities to meet the higher production needs


10/22

Product Pipeline

IC

Viral Load HIV I

Viral Load HIV II

TB (PCR)

TB (MODS)

Stage Patent CDSCO

Approval

Launch

Produce Granted (India) Yes 6 months postfunding

Clinical trial

Apply Post

funding

Projected 6

months post

funding

18 months post

patent

application

Clinical trial

Apply Post

funding

Projected 6

months post

funding

18 months post

patent

application

Clinical trial

Apply Post

funding

Projected 6months post

funding

18 months postpatent

application

Clinical trial

Apply Post

funding

Projected 6

months post

funding

18 months post

patent

application

Applying core competencies to develop simplified testing solutions


11/22

Opportunity

Significant market The burden of infectious diseases is high in developing countries.

Low financial and technical resources to meet the widespread need in rural areas

Relationships The Companys founders and directors are well-known to product buyers in Africa, Asia, and

Latin America

Practical solution The lack of cost effective competitive products is an advantage Current products offerings require high technical talent and are expensive to reach the rural

areas in developing world

Market need The company is well positioned to fulfill the desperate market need with proper attention

and focus Desperate need by world agencies for low cost solutions


12/22

Appendix


13/22

Management

Dr. Subhash Hira is a medical doctor who specialized in Infectious Diseases and

Public Health from Baroda, UK and the US. He has had a distinguished career of 30

years during which he has held senior positions with the Zambian Ministry ofHealth, Uniformed Services University, Bethesda; the University of Texas-Houston;The World Bank, Washington DC; The World Health Organization; and UNICEFamong a host of UN and multi-lateral agencies. Dr. Hira has the cross-culturalexperience of living and working in challenging environments. For most of his career

he has been involved with HIV/AIDS, tuberculosis and other Infectious Diseasesand has several firsts to his credit, from published evidence in 1982 that HIV washeterosexually transmitted among Africans, to starting ART in India in 1996. He hasover 100 scientific publications in international journal and has contributedchapters in international medical text books.

Presently, Dr. Hira is consulting with the World Bank and the Global Fund on healthprograms.


14/22

Management

Mr. Harish Mamtani is the Managing Director of Bluefish Capital, LLC. Mr. Mamtani launchedthe firm in July 2005 to offer independent and objective advice to family offices and high networth clients on their global portfolios. In his role, Mr. Mamtani created diversified portfolioscomprising of liquid instruments, hedge funds (direct and fund of funds), global private equity,and real estate. In addition, Mr. Mamtani managed direct investments for his clients in thetechnology, healthcare, and real estate sectors.

In January 2009, Mr. Mamtani joined IC as its CEO.

Prior to Bluefish Capital, LLC, Mr. Mamtani co-managed a team at Bank of America Private

Bank where they advised bank clients on investments. Mr. Mamtanis team managed $960million for banks clients. Mr. Mamtani began his career in wealth management in 1998 withMerrill Lynch and subsequently his entire team moved to Morgan Stanley.

Mr. Mamtani began his professional career with Price Waterhouse as a Management Consultant.Mr. Mamtani worked with sophisticated software packages such as SAP, PeopleSoft, and Oracle

in fields of EDI, Finance, and Human Resources.

Mr. Mamtani has a BA in Accounting and Master of International Business Studies (MIBS) fromthe University of South Carolina.

Mr. Mamtani served as 2007 President for TiE Atlanta and has been a Charter Member since

2005. From 2002 to 2006, Mr. Mamtani was the President of the Atlanta High Tech CEOCouncil in Atlanta, GA.


15/22

Adults and Children living with HIV worldwide


16/22

Market Conditions

June 2005 Between 2001 and 2005, the number of people on antiretroviral therapy (ART)

in low and middle-income countries increased more than fivefold

From 240,000 to approximately 1.3 million (Figure 7.1 next page)

21 countries were providing ART to 50% of those in clinical need (WHO andUNAIDS, 2005)

In Africa, the number of people on ART more than doubled in 2005 alone

Only one in six people who needed treatment received ART by December2005

Nearly 200 sites in Kenya were providing ART by December 2005

In South Africathe country with the largest population of people living withHIVthe number of people receiving ART grew from fewer than 5,000 at thebeginning of 2004 to roughly 190,000 by the end of 2005

2007

There are approximately 3 million people on ART


17/22

PLWHA receiving therapy


18/22

Global Funding

Financing AIDS globally Resource requirements in 2007 are estimated to be US$ 18.1 billion, while

resources expected to be available for the same year are estimated at US$10 billion. This highlights the need for cost effective offerings.


19/22

Product Pipeline

TB Monitoring product 2 TB products

TB PCR TB MODS

Patent application to begin in upon funding

CDSCO approval submission to begin upon funding

Tuberculosis There are 9 million new cases of TB each year.

One-third of new TB cases occur in Southeast Asia

Estimated incidence per capita is highest in sub-Saharan Africa Highest number of estimated deaths due to TB and the highest mortality

per capita are in Africa, where HIV has led to rapid increases in TBincidence. Source: World Health Organization (WHO).


20/22

ImmediateTarget Market

South Africa

India

Mozambique

Zimbabwe

Tanzania

Kenya

Zambia

Uganda

Congo

Countries marked in bluerepresent IC activity

Countries marked in redrepresent target market

Country HIV Cases

South Africa 5,500,000

India 2,500,000Mozambique 1,800,000

Zimbabwe 1,700,000

Tanzania 1,400,000

Kenya 1,300,000

Zambia 1,100,000

Uganda 1,000,000Congo 1,000,000

Russian 940,000

Ethiopia 750,000

Cte d`Ivoire 750,000

China 650,000

Brazil 620,000

Thailand 580,000

Cameroon 510,000

Myanmar 360,000

Angola 320,000

Ghana 320,000

Vietnam 260,000

Central African Republic 250,000Namibia 230,000

Swaziland 220,000

Rwanda 190,000

Haiti 190,000

Mexico 180,000

Cambodia 130,000Total 24,750,000


21/22

Process


22/22

Use of Proceeds

IC will be launched with $2 million funding and will seek to fund otherproduct initiatives from internal cash flow and grants.

$5 million is required for fully funded plan for all current and futureproducts (needs subject to change depending on final relationships

established for outsourcing)

$1,000,000 to establish new facilities in India

$1,000,000 to complete the is patent and CDSCO approval process

for 4 products that have been clinically tested $1,000,000 R&D for new products

$1,000,000 to launch sales and marketing initiatives

$1,000,000 working capital

Immunocount Presentation

Documents